FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB Number: 3235-0287 ΙP Estimated average burden

**OMB APPROVAL** 

hours per response:

	Check this box if no longer subject to
١	Section 16. Form 4 or Form 5
	obligations may continue. See
	Instruction 1/h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Payne Joseph E  (Last) (First) (Middle)  C/O ARCTURUS THERAPEUTICS HOLDINGS						2. Issuer Name and Ticker or Trading Symbol     Arcturus Therapeutics Holdings Inc. [ ARCT ]      3. Date of Earliest Transaction (Month/Day/Year)     06/21/2022						Relationship of Reporting Perscheck all applicable)  X Director  X Officer (give title below)  President and		10% Ow Other (s <sub>i</sub> below)	ner	
INC. 10628 SCIENCE CENTER DRIVE, SUITE 250						If Amendment, Date of Original Filed (Month/Day/Year)						Individual or Joint/Group Filing (Check Applicable				
(Street) SAN DII	92121 (Zip)								Line)	· I						
	(City) (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
1. Title of Security (Instr. 3)  2. Trans: Date						2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr. 8)		Of (D) (Inst	r. 3, 4 and 5)	Beneficial Owned Fo Reported	ly (D) (I) (	m: Direct I or Indirect I Instr. 4)	7. Nature of ndirect Beneficial Ownership Instr. 4)	
								Code V	Amount	(A) or (D)	Price	Transactio				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. r) 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)			
Employee Stock Option (right to buy)	\$34.57	06/21/2022		A		150,000(1)		(2)	12/10/2031	Common Stock	150,000	\$0.00	150,000	D		

## **Explanation of Responses:**

- 1. Represents options to purchase shares of common stock conditionally approved by the Board of Directors on December 10, 2021, subject to approval of an amendment to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan by the Company's stockholders, which approval was obtained at the Company's 2022 Annual Meeting of Stockholders held on June 21, 2022.
- 2. The shares underlying this option vest 25% on December 10, 2022, the first anniversary of the date this award was conditionally approved by the Board of Directors, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

/s/ Ilan Katz, attorney-in-fact 06/23/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.